Novel insights into how exercise functions as an antidepressant

Un­der new CEO Bill An­der­son, Bay­er re­mains com­mit­ted to be­com­ing a top 10 on­col­o­gy play­er, and the road to do­ing so will be paved by

No­var­tis is be­ing ac­cused of de­lib­er­ate­ly stalling the de­vel­op­ment of an ac­quired IL-15 as­set, cost­ing a small­er biotech up to $940 mil­lion in mile­stone pay­ments

Share this article The Inhibrx acquisition is expected to bolster Sanofi’s portfolio in rare diseases and oncology. Credit: nitpicker / Shutterstock.com. Sanofi has signed an